Bristol Myers Squibb Net Income 2010-2025 | BMY

Bristol Myers Squibb net income for the twelve months ending March 31, 2025 was $5.419B, a 188.14% decline year-over-year.

  • Bristol Myers Squibb annual net income for 2024 was $-8.948B, a 211.5% decline from 2023.
  • Bristol Myers Squibb annual net income for 2023 was $8.025B, a 26.84% increase from 2022.
  • Bristol Myers Squibb annual net income for 2022 was $6.327B, a 9.54% decline from 2021.

Bristol Myers Squibb Net Income 2010-2025 | BMY

  • Bristol Myers Squibb annual net income for 2024 was $-8.948B, a 211.5% decline from 2023.
  • Bristol Myers Squibb annual net income for 2023 was $8.025B, a 26.84% increase from 2022.
  • Bristol Myers Squibb annual net income for 2022 was $6.327B, a 9.54% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$213.3B
Amgen (AMGN)$158.5B
Gilead Sciences (GILD)$134.6B
Vertex Pharmaceuticals (VRTX)$118.1B
CSL (CSLLY)$81.2B
GSK (GSK)$74.3B
Regeneron Pharmaceuticals (REGN)$58.6B
Alnylam Pharmaceuticals (ALNY)$41.8B
Argenex SE (ARGX)$34.6B
BioNTech SE (BNTX)$26.4B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.3B
Illumina (ILMN)$15.2B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$14B
Incyte (INCY)$13.1B
Exelixis (EXEL)$12.1B
Moderna (MRNA)$12.1B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.4B
Exact Sciences (EXAS)$9.5B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.2B
Roivant Sciences (ROIV)$7.8B
Legend Biotech (LEGN)$7.6B
Regencell Bioscience Holdings (RGC)$7.2B